A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

The purpose of this study is to evaluate complete molecular response of Dasatinib in patients for Philadelphia chromosome-positive chronic myeloid leukemia

Inclusion Criteria:

• Chronic Myeloid Leukemia in the Chronic Phase
• 20 years old over
• ECOG performance status (PS) score 0-2
• Patients for major molecular response (MMR) with no CMR
• Adequate organ function (hepatic, renal and lung)
• Signed written informed consent

Exclusion Criteria:

• A case with the double cancer of the activity

• Women who are pregnant or breastfeeding

• The case of Pleural effusion clearly

• Patients with complications or a history of severe or uncontrolled cardiovascular failure following

  • have a Myocardial infarction within 6 months
  • have an Angina within 3 months
  • have a Congestive heart failure within 3 months
  • have a suspected congenital QT syndrome
  • have a QTc interval of more than 450msec at baseline

• A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy

• Prior treatment with dasatinib

• Subjects with T315I, F317L and V299L BCR-ABL point mutations